In vivo and in vitro processing of recombinant pro-von Willebrand factor

Histochemistry and Cell Biology

Volumn 117, Issue 2, 2002, Pages 123-129

  Turecek, Peter L ^a   Varadi, Katalin ^a   Schlokat, Uwe ^a   Pichler, Ludwig ^a   Dorner, Friedrich ^a   Schwarz, Hans ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

pro vWF; Processing; Propeptide; Thrombin; Von Willebrand factor

Indexed keywords

COLLAGEN; HIRUDIN; PROTEIN ANTIBODY; PROTEIN PRECURSOR; RECOMBINANT PROTEIN; THROMBIN; VON WILLEBRAND FACTOR;

ANTIGEN BINDING; CIRCULATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN SYNTHESIS;

ANIMALS; HUMANS; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; THROMBIN; VON WILLEBRAND FACTOR;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036186368     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-001-0375-x     Document Type: Article

References (61)

1. Binding of factor VIII to von Willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers
2. Collagen-bound von Willebrand factor has reduced affinity for factor VIII
3. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans
4. Factor XI activation by meizothrombin: Stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine
5. Evidence that meizothrombin is an intermediate product in the clotting of whole blood
6. Receptor-associated protein: A specialized chaperone and antagonist for members of the LDL receptor gene family
7. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis
8. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers
9. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
10. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemophilic-uremic syndrome
11. Binding of human factor VIII to phospholipid vesicles
12. Human von Willebrand factor (vWF): Isolation of complementary DNA (cDNA) clones and chromosomal localization
13. Protein C activation on endothelial cells by prothrombin activation products generated in situ: Meizo-thrombin is a better protein C activator than α-thrombin
14. Propolypeptide of von Willebrand factor is a novel ligand for very late antigen-4 integrin
15. Von Willebrand's disease in dogs
16. The influence of fibrinogen and fibrin on thrombin generation: Evidence for feedback activation of the clotting system by clot bound thrombin
17. Precise chromosomal locations of the genes for dentatorubral-pallidoluysian atrophy (DRPLA), von Willebrand factor (F8vWF) and parathyroid hormone-like hormone (PTHLH) in human chromosome 12p by deletion mapping
18. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII
19. The life cycle of coagulation factor VIII in view of its structure and function
20. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein
21. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
22. Structure of the gene for human von Willebrand factor
23. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib
24. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly
25. Distinct structural attributes regulating von Willebrand factor A1 domain interaction with platelet glycoprotein Ibα under flow
26. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
27. Mvwf, a domain modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase
28. Von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation
29. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vitro
30. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo
31. Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor
32. Von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene
33. Recombinant von Willebrand factor: Preclinical development
34. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes
35. Identification of mutation in the canine von Willebrand factor gene causing type III von Willebrand disease
36. Developing basic and clinical research on von Willebrand factor and von Willebrand disease
37. The structure and function of von Willebrand factor
38. Von Willebrand factor
39. Biochemistry and genetics of von Willebrand factor
40. Haemophilia A, haemophilia B, and von Willebrand disease
41. Impact, diagnosis and treatment of von Willebrand disease
42. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice
43. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor
44. Inducible secretion of large, biologically potent von Willebrand factor multimers
45. Factor VIII activity in canine von Willebrand disease
46. The RIIIS/J inbred mouse strain as a model for von Willebrand disease
47. Activation of human factor V by meizothrombin
48. Meizothrombin formation during factor Xa-catalyzed prothrombin activation
49. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
50. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
51. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease
52. Thrombin-mediated in vitro processing of pro-von Willebrand factor
53. Proteolytic cleavage of the precursor of von Willebrand factor is not essential for multimer formation
54. Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWF:AgII) levels
55. Kinetics of factor VIII-von Willebrand factor association
56. Domains involved in multimer assembly of von Willebrand factor (vWF): Multimerization is independent of dimerization
57. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization
58. Stabilization of factor VIII in plasma by the von Willebrand factor
59. Expression of a human proprotein processing enzyme: Correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site
60. The role of von Willebrand factor multimer and propeptide cleavage in binding and stabilization of factor VIII
61. Cellular uptake and degradation of the thrombin activated factor VIII fragments